Rate Video

EORTC CLTF 2021 | Pegylated liposomal doxorubicin as maintenance in mycosis fungoides

Pablo Ortiz Romero • 14 Oct 2021

EORTC CLTF 2021

Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Pegylated liposomal doxorubicin

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, talks on the use of pegylated liposomal doxorubicin as maintenance treatment for patients with mycosis fungoides, a subtype of cutaneous T-cell lymphoma (CTCL). Prof. Orbitz reports that pegylated liposomal doxorubicin has shown promise as a maintenance therapy. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab

Pablo Ortiz Romero • 14 Oct 2021

Quality of life in cutaneous lymphoma patients: patient-reported outcomes

Pablo Ortiz Romero • 27 Sep 2018

RESMAIN: resmonistat for CTCL maintenance

Pablo Ortiz Romero • 14 Oct 2021

Approval of brentuximab vedotin for CD30+ mycosis fungoides

Pablo Ortiz Romero • 14 Oct 2021

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

CD19 CAR T-cell therapy for lymphoma

Michael Schmitt

Axicabtagene ciloleucel in the real-world: safety and efficacy